search
Back to results

Electrocardiogram Clinical Validation Study

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Electrocardiogram
Sponsored by
Garmin International
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Atrial Fibrillation

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Able to read, understand, and provide written informed consent;
  • Willing and able to participate in the study procedures as described in the consent form;
  • Individuals who are 22 years of age and older;
  • Able to communicate effectively with and follow instructions from the study staff;
  • Have a wrist circumference that fits within the device band; and
  • For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening.

Exclusion Criteria:

  • Physical disability that precludes safe and adequate testing;
  • Mental impairment resulting in limited ability to cooperate;
  • Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD);
  • Acute myocardial infarction within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable;
  • Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening;
  • Stroke or transient ischemic attack within 90 days of screening;
  • Subjects taking rhythm control drugs;
  • Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis, or allergic contact dermatitis on both wrists or over electrode attachment sites, including known allergy or sensitivity to silicone bands primarily used in wrist-worn fitness devices;
  • Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or ECG electrodes;
  • A history of abnormal life-threatening rhythms as determined by the Investigator;
  • Significant tremor that prevents subject from being able to hold still;
  • Women who are pregnant at the time of study participation; and
  • Subjects enrolled into the SR population must not have any diagnosis of AF.

Sites / Locations

  • Hope Research Institute
  • MedStar Washington Hospital Center
  • HealthEast
  • Northwell Health North Shore University Hospital
  • Northwell Health Lenox Hill Hospital
  • MedStar Health Cardiac Electrophysiology at Fairfax

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Atrial fibrillation (AF)

Normal Sinus Rhythm (SR)

Arm Description

Patients with a known history of AF who are in AF at the time of study screening.

Patients with no known diagnosis of AF or other arrhythmia

Outcomes

Primary Outcome Measures

Specificity of rhythm classification
Number of participants with a SR software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG
Sensitivity of rhythm classification
Number of participants with an AF software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG

Secondary Outcome Measures

Number of ECGs that pass a visual overlay
Number of participants with software's ability to produce a clinically equivalent waveform in agreement to a gold standard Lead I reference
Difference in R-wave amplitudes between the software and gold standard reference
Number of participants with software's ability to produce a clinically equivalent waveform in agreement to a gold standard Lead I reference

Full Information

First Posted
April 8, 2021
Last Updated
February 2, 2022
Sponsor
Garmin International
search

1. Study Identification

Unique Protocol Identification Number
NCT04842123
Brief Title
Electrocardiogram Clinical Validation Study
Official Title
Electrocardiogram Clinical Validation Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
March 31, 2021 (Actual)
Primary Completion Date
October 4, 2021 (Actual)
Study Completion Date
October 4, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Garmin International

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to confirm the Garmin ECG (electrocardiogram) software algorithm can detect and classify atrial fibrillation and normal sinus rhythm on single lead ECG data derived from a Garmin wrist-worn, consumer device. The study will also confirm the software's ability to create a Lead I ECG that is clinically equivalent to a reference device. The Garmin ECG software is not a diagnostic system and is intended for informational purposes only.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
568 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Atrial fibrillation (AF)
Arm Type
Other
Arm Description
Patients with a known history of AF who are in AF at the time of study screening.
Arm Title
Normal Sinus Rhythm (SR)
Arm Type
Other
Arm Description
Patients with no known diagnosis of AF or other arrhythmia
Intervention Type
Diagnostic Test
Intervention Name(s)
Electrocardiogram
Intervention Description
Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
Primary Outcome Measure Information:
Title
Specificity of rhythm classification
Description
Number of participants with a SR software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG
Time Frame
1 Day
Title
Sensitivity of rhythm classification
Description
Number of participants with an AF software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG
Time Frame
1 Day
Secondary Outcome Measure Information:
Title
Number of ECGs that pass a visual overlay
Description
Number of participants with software's ability to produce a clinically equivalent waveform in agreement to a gold standard Lead I reference
Time Frame
Day 1
Title
Difference in R-wave amplitudes between the software and gold standard reference
Description
Number of participants with software's ability to produce a clinically equivalent waveform in agreement to a gold standard Lead I reference
Time Frame
Day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Able to read, understand, and provide written informed consent; Willing and able to participate in the study procedures as described in the consent form; Individuals who are 22 years of age and older; Able to communicate effectively with and follow instructions from the study staff; Have a wrist circumference that fits within the device band; and For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening. Exclusion Criteria: Physical disability that precludes safe and adequate testing; Mental impairment resulting in limited ability to cooperate; Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD); Acute myocardial infarction within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable; Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening; Stroke or transient ischemic attack within 90 days of screening; Subjects taking rhythm control drugs; Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis, or allergic contact dermatitis on both wrists or over electrode attachment sites, including known allergy or sensitivity to silicone bands primarily used in wrist-worn fitness devices; Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or ECG electrodes; A history of abnormal life-threatening rhythms as determined by the Investigator; Significant tremor that prevents subject from being able to hold still; Women who are pregnant at the time of study participation; and Subjects enrolled into the SR population must not have any diagnosis of AF.
Facility Information:
Facility Name
Hope Research Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85018
Country
United States
Facility Name
MedStar Washington Hospital Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
HealthEast
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55102
Country
United States
Facility Name
Northwell Health North Shore University Hospital
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Facility Name
Northwell Health Lenox Hill Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States
Facility Name
MedStar Health Cardiac Electrophysiology at Fairfax
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Electrocardiogram Clinical Validation Study

We'll reach out to this number within 24 hrs